Victoria Socha

DocwireNews

Patients admitted to inpatient hospital care commonly present with hyperkalemia. According to Abdullah Bin Huda, MMBA, MRCP, and colleagues in the United Kingdom, there are few data available supporting commonly utilized treatment strategies for that patients hospitalized with acute hyperkalemia.The National Institute for Health and Care Excellence (NICE) has recommended the use of sodium zirconium cyclosilicate (SZC) (TA599) and patiromer (TA623) in both acute and chronic hyperkalemia, there are few data on their use in acute hyperkalemia in the hospital setting, particularly when compared with the current standard of care, calcium polystyrene (CPS).The researchers conducted a retrospective review of the electronic patient record system at the University Hospitals of Leicester NHS Trust over a 6-month period to examine the efficacy and cost effectiveness of treatments. Results were reported online in the Journal of Clinical Pharmacy and Therapeutics [doi.org/10.1111/jcpt.13766].The review identified 138 patients who were treated with either SCZ (n=65) or CPS (n=73) to manage hyperkalemia. Simple descriptive statistics were used to analyze results. A na&iuml;ve cost comparison between the two agents was made based on the analysis results.CPS was used to treat patients with potassium level 6.07 mmol/L and SZC was used to treat patients with potassium 6.03 mmol/L. The principle causes of hyperkalemia were acute kidney injury, medication, and chronic kidney disease.Reduction of plasm potassium concentrations in patients with hyperkalemia was effective with both CPS and SZC: CPS reduced potassium concentration by 1.17 mmol/L and SCZ reduced potassium concentration by 1.24 mmol/L. Time to work was similar in the two agents (2.97 days vs 3 days, respectively).Cost comparison analyses that accounted for raw product price and time needed to dispense the medication revealed that CPS was slightly more cost-effective compared with SZC; although CPS was associated with the cost of increased staff input.In summary, the authors said, &ldquo;Both CPS and SZC were equally effective at lowering acutely raised potassium concentrations. The cost difference between the two products appears to be small. Claims regarding the benefits of newer agents over older established medications need to be properly explored in randomized trials rather than being based on small scale noncomparative studies.&rdquo;

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Treating Acute Hyperkalemia in the Hospital Setting

Hyperkalemia

Patients admitted to inpatient hospital care commonly present with hyperkalemia. According to Abdullah Bin Huda, MMBA, MRCP, and colleagues in the United Kingdom, there are ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe